TriangleAvutometinib (NCT06394804)
Avutometinib trial for Low-Grade Serous Ovarian Cancer (NCT06394804). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with low-grade serous ovarian or peritoneal cancer, without prior systemic treatment. They must be unsuitable for initial surgery or have measurable cancer left after attempted removal.
The idea: combine oral avutometinib and defactinib to block growth signals, plus letrozole to reduce estrogen. Some premenopausal patients also need ovarian suppression. Researchers measure tumor response and safety.
This phase 2 study plans 20 patients. Rachel Grisham leads at Memorial Sloan Kettering in New York. Eight US locations are marked recruiting; six allow only limited protocol activities.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.